47 related articles for article (PubMed ID: 21410068)
21. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.
Chuang JY; Yang SS; Lu YT; Hsieh YY; Chen CY; Chang SC; Chang CS; Yeh HZ; Kao JH
Dig Liver Dis; 2009 Jun; 41(6):424-30. PubMed ID: 19004675
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
Lee HJ; Eun JR; Choi JW; Kim KO; Moon HJ
Korean J Hepatol; 2008 Mar; 14(1):46-57. PubMed ID: 18367857
[TBL] [Abstract][Full Text] [Related]
23. Outcome in partial early virologic responders to combination therapy with peginterferon and ribavirin in patients infected with hepatitis C virus genotype 1b.
Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Hosokawa T; Arakawa T; Fujimori M
J Med Virol; 2011 Jan; 83(1):101-7. PubMed ID: 21108345
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
25. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
[TBL] [Abstract][Full Text] [Related]
26. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin.
Weiland O; Hollander A; Mattsson L; Glaumann H; Lindahl K; Schvarcz R; Lindh G; Enquist R; Quist A
J Viral Hepat; 2008 Sep; 15(9):641-5. PubMed ID: 18507753
[TBL] [Abstract][Full Text] [Related]
27. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
[TBL] [Abstract][Full Text] [Related]
28. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
Rossignol JF; Elfert A; El-Gohary Y; Keeffe EB
Gastroenterology; 2009 Mar; 136(3):856-62. PubMed ID: 19135998
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.
Buti M; Lurie Y; Zakharova NG; Blokhina NP; Horban A; Teuber G; Sarrazin C; Balciuniene L; Feinman SV; Faruqi R; Pedicone LD; Esteban R;
Hepatology; 2010 Oct; 52(4):1201-7. PubMed ID: 20683847
[TBL] [Abstract][Full Text] [Related]
30. [Retreatment options for patients with chronic hepatitis C].
Hrstić I; Ostojić R; Vucelić B
Acta Med Croatica; 2009 Dec; 63(5):417-22. PubMed ID: 20198901
[TBL] [Abstract][Full Text] [Related]
31. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
32. Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus.
Hevezi PA; Tom E; Wilson K; Lambert P; Gutierrez-Reyes G; Kershenobich D; Zlotnik A
Autoimmunity; 2011 Nov; 44(7):532-42. PubMed ID: 21864061
[TBL] [Abstract][Full Text] [Related]
33. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.
Chen L; Borozan I; Feld J; Sun J; Tannis LL; Coltescu C; Heathcote J; Edwards AM; McGilvray ID
Gastroenterology; 2005 May; 128(5):1437-44. PubMed ID: 15887125
[TBL] [Abstract][Full Text] [Related]
34. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
Younossi ZM; Birerdinc A; Estep M; Stepanova M; Afendy A; Baranova A
J Transl Med; 2012 Feb; 10():25. PubMed ID: 22313623
[TBL] [Abstract][Full Text] [Related]
35. Application of interferon response-related gene array to the antiviral treatment outcome in chronic hepatitis C.
Xing TJ; Xv HT; Zhao W; Shen L; Li H; Cai RT
Hepatogastroenterology; 2010; 57(102-103):1257-63. PubMed ID: 21410068
[TBL] [Abstract][Full Text] [Related]
36. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H
J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
[TBL] [Abstract][Full Text] [Related]
38. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
[TBL] [Abstract][Full Text] [Related]
39. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
[TBL] [Abstract][Full Text] [Related]
40. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
